Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

Dear ORPH Stock Fans, Here Is the Latest Trial News You Should Be Cheering

Today, ORPH stock is trading significantly higher after the company announced some positive clinical trial data for its lead drug candidate.

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

AITX Stock: 7 Things to Know About the AI Penny Stock as Shares Soar

Today, shares of Artificial Intelligence Technology Solutions and AITX stock are soaring, as investors jump into risk-on assets.

PROG Stock: 2 Reasons Why Progenity Investors Are Crying as the Penny Stock Plunges

Today, a number of factors appear to be behind the massive downside move of more than 50% in biotech play PROG stock.

RIDE Stock: Lordstown Motors Shares Rev Up Amid r/WSB Chatter

Today, investors in Lordstown Motors and RIDE stock are seeing impressive gains, as retail investors jump into this embattled stock.